0001209191-20-064857.txt : 20201222
0001209191-20-064857.hdr.sgml : 20201222
20201222165526
ACCESSION NUMBER: 0001209191-20-064857
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201221
FILED AS OF DATE: 20201222
DATE AS OF CHANGE: 20201222
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ho Tony W
CENTRAL INDEX KEY: 0001713637
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37923
FILM NUMBER: 201408743
MAIL ADDRESS:
STREET 1: CRISPR THERAPEUTICS AG
STREET 2: 610 MAIN STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CRISPR Therapeutics AG
CENTRAL INDEX KEY: 0001674416
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 473173478
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
BUSINESS PHONE: 6173154600
MAIL ADDRESS:
STREET 1: BAARERSTRASSE 14
CITY: ZUG
STATE: V8
ZIP: CH-6300
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-12-21
0
0001674416
CRISPR Therapeutics AG
CRSP
0001713637
Ho Tony W
C/O CRISPR THERAPEUTICS, INC.
610 MAIN STREET
CAMBRIDGE
MA
02139
0
1
0
0
Executive VP, Head of R&D
Common Shares
2020-12-21
4
M
0
23551
16.90
A
57515
D
Common Shares
2020-12-21
4
S
0
1700
148.11
D
55815
D
Common Shares
2020-12-21
4
S
0
900
149.18
D
54915
D
Common Shares
2020-12-21
4
S
0
1600
150.16
D
53315
D
Common Shares
2020-12-21
4
S
0
1100
151.58
D
52215
D
Common Shares
2020-12-21
4
S
0
500
152.41
D
51715
D
Common Shares
2020-12-21
4
S
0
1400
147.05
D
50315
D
Common Shares
2020-12-21
4
S
0
8400
148.38
D
41915
D
Common Shares
2020-12-21
4
S
0
5000
149.73
D
36915
D
Common Shares
2020-12-21
4
S
0
2951
150.61
D
33964
D
Stock Option (right to buy)
16.90
2020-12-21
4
M
0
23551
0.00
D
2027-08-01
Common Shares
23551
236449
D
Includes 217 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.44 to $148.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.69 to $149.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.755 to $150.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.00 to $151.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.04 to $152.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.00 to $147.125, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.19 to $149.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.20 to $150.195, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.44 to $151.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
This option was granted on August 1, 2017 with respect to 260,000 Common Shares of which 25% vested on 8/1/2018 and the remaining 75% vest in 36 equal monthly installments on the final day of each succeeding calendar month.
/s/ Michael Esposito, attorney-in-fact
2020-12-22